Triparna Sen: CD38-mediated immunosuppression as a potential mechanism of tumor cell escape from PDL1 inhibition in SCLC

Triparna Sen, Associate Professor, Icahn School of Medicine at Mount Sinai, shared a post on X:

“I am happy to share our brief report in Frontiers – Immunology highlighting the role of CD38-mediated immunosuppression as a potential mechanism of tumor cell escape from PDL1 inhibition in small-cell lung cancer.

SCLC is characterized by an immunosuppressed phenotype and immunotherapy with or without chemotherapy often has a modest benefit in only a minority of patients.

Our study provides preliminary evidence and a future direction for exploring: CD38 as a potential biomarker of ICB resistance… CD38 blockade as a potential combination strategy for chemoimmunotherapy in SCLC…

The work was led by a fantastic postdoc Dr. Hirokazu Taniguchi and I am grateful to all my co-authors- Drs. Shweta Chavan, Andrew Chow, Joseph Chan, Hiroshi Mukae, and Charles M. Rudin for their help and support.  The underlying mechanism of ubiquitous immune escape in SCLC and biomarkers of immunotherapy response is an active area of investigation at the Sen Lab.”

Role of CD38 in anti-tumor immunity of small cell lung cancer

Authors: Hirokazu Taniguchi, Shweta S. Chavan, Andrew Chow, Joseph M. Chan, Hiroshi Mukae, Charles M. Rudin and Triparna Sen.